<span item_type="fundamental" item_id="6b144adb2e2b5c7e41642517d564105f" counter_id="ST/US/AEON" env="prod"></span><span item_type="announcement" item_id="582682354377951105" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.39.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -2.493 M.</p><p></p><h3>Financial Metrics by Segment</h3><h4>Segment Revenue</h4><ul><li>Not explicitly detailed in the provided reference.</li></ul><h4>Operational Metrics</h4><ul><li><strong>Net Loss</strong>: For the three months ended September 30, 2025, net loss was $4,538 thousand, compared to a net loss of $6,171 thousand for the same period in 2024. For the nine months ended September 30, 2025, net loss was $2,085 thousand, compared to a net income of $39,923 thousand for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114xex99d1.htm"></span></li><li><strong>Operating Costs and Expenses</strong>: Total operating costs and expenses for the three months ended September 30, 2025, were $2,493 thousand, compared to $4,016 thousand for the same period in 2024. For the nine months ended September 30, 2025, total operating costs and expenses were $7,292 thousand, compared to - $75,306 thousand for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114xex99d1.htm"></span></li><li><strong>Operating Loss</strong>: For the three months ended September 30, 2025, operating loss was $2,493 thousand, compared to an operating loss of $4,016 thousand for the same period in 2024. For the nine months ended September 30, 2025, operating loss was $7,292 thousand, compared to an operating income of $75,306 thousand for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114xex99d1.htm"></span></li></ul><h4>Cash Flow</h4><ul><li><strong>Cash and Cash Equivalents</strong>: As of September 30, 2025, cash and cash equivalents were $5,927 thousand, compared to $13 thousand as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114xex99d1.htm"></span></li></ul><h4>Unique Metrics</h4><ul><li><strong>Convertible Notes</strong>: Convertible notes at fair value, including related party amounts, were $17,051 thousand as of September 30, 2025, compared to $11,689 thousand as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114xex99d1.htm"></span></li><li><strong>Warrant Liability</strong>: Warrant liability was $2,338 thousand as of September 30, 2025, compared to $1,187 thousand as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114xex99d1.htm"></span></li></ul><h4>Outlook / Guidance</h4><ul><li>AEON Biopharma expects the recent $6 million PIPE financing and proposed Daewoong note exchange to strengthen its balance sheet, reduce outstanding debt by more than 90%, and extend its cash runway into the second quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114xex99d1.htm"></span></li><li>The company has an FDA Type 2a meeting scheduled for November 19, 2025, to review its analytical development plan and initial data.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114xex99d1.htm"></span></li><li>AEON Biopharma aims to accelerate the ABP-450 biosimilar program by up to six months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114xex99d1.htm"></span></li></ul>

AEON Biopharma, Inc. | 8-K: FY2025 Q3 Revenue: USD 0